Semaglutide dosage in published studies and labels

These are the doses used for Semaglutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: September 5, 2026

Studied regimens and sources

Semaglutide has an FDA-approved human dosage. Approved subcutaneous dosing differs by product and indication: Ozempic is titrated from 0.25 mg to a maximum of 2 mg once weekly for type 2 diabetes, and Wegovy is titrated to a 2.4 mg once-weekly maintenance dose for weight reduction and cardiovascular risk reduction, with escalation to a maximum of 7.2 mg once weekly permitted for weight reduction in adults.

FDA Approved

Dosage evidence summary for Semaglutide
Human dosing established	Yes
Studied dose range	0.25–7.2 mg once weekly, depending on product and indication
Route	Subcutaneous
Frequency	Once weekly
Duration studied	Continuous; titration reaches maintenance at week 17 (Wegovy)
Titration	Wegovy: 0.25 mg weeks 1–4, 0.5 mg weeks 5–8, 1 mg weeks 9–12, 1.7 mg weeks 13–16, maintenance from week 17. Ozempic: 0.25 mg for 4 weeks, then 0.5 mg, then 1 mg, then 2 mg, each step after at least 4 weeks.
Half-life	Approximately 1 week
Evidence level	FDA Approved
Last reviewed	2026-09-05

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Semaglutide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Wegovy, weight reduction in adultsFDA-approved label · FDA prescribing information	Adults with obesity, or overweight with a weight-related condition	2.4 mg maintenance (1.7 mg alternative); maximum 7.2 mg	Subcutaneous	Once weekly	Escalated over 16 weeks, then continuous	Chronic weight management	WEGOVY (semaglutide) injection — FDA prescribing information, DailyMed
FDA label — Wegovy, cardiovascular risk reductionFDA-approved label · FDA prescribing information	Adults with established cardiovascular disease and obesity or overweight	2.4 mg (recommended) or 1.7 mg	Subcutaneous	Once weekly	Continuous	Major adverse cardiovascular events	WEGOVY (semaglutide) injection — FDA prescribing information, DailyMed
FDA label — Ozempic, type 2 diabetesFDA-approved label · FDA prescribing information	Adults with type 2 diabetes mellitus	0.5 mg, 1 mg or 2 mg maintenance; maximum 2 mg	Subcutaneous	Once weekly	Continuous; 0.25 mg for the first 4 weeks is a starting dose, not a maintenance dose	Glycaemic control; cardiovascular and renal outcomes	OZEMPIC (semaglutide) injection — FDA prescribing information, DailyMed
STEP 1 — phase 3 randomised trial (Wilding et al., 2021)Clinical trial · Phase 3 double-blind randomised controlled trial	Adults with BMI ≥30, or ≥27 with a weight-related condition, without diabetes	2.4 mg	Subcutaneous	Once weekly	68 weeks	Percentage change in body weight	Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.

Where sources disagree

Maximum approved dose differs by product and indication: 2 mg once weekly under the Ozempic label versus up to 7.2 mg once weekly for weight reduction in adults under the Wegovy label. A dose that is above the ceiling for one product is within the label for another, so a single "maximum semaglutide dose" figure is not meaningful without naming the product and indication.
The 0.25 mg starting dose is an escalation step in both labels and is explicitly not intended as a maintenance dose. It is sometimes quoted elsewhere as a standalone low-dose protocol, which the labelling does not support.